Navigation Links
Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
Date:9/11/2007

Generic Erosion of Zocor and Lipitor Will Cause Market Share of Statins to Drop Nearly 40% by 2016, According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease (PAD).

The new Pharmacor report Peripheral Arterial Disease finds that Genzyme's HIF-1 alpha therapy for PAD patients with intermittent claudication, which could reach the market as early as 2010, will garner sales of $1.5 billion in 2016 in the world's major pharmaceutical markets. Experts are optimistic about the market entry of novel angiogenic therapies, which act by generating new blood vessels in the legs and are the first agents to be developed as disease- modifying therapies for PAD. Although numerous studies will be required to establish the efficacy and safety of angiogenic products, physicians are hopeful these pioneering, PAD-specific therapies will be effective in treating the intermittent claudication and critical limb ischemia patient segments.

The report also finds that although statins will continue to dominate the PAD prescription landscape, the U.S. patent expiries of Merck's Zocor in 2006 and Pfizer's Lipitor in 2010 will cause total statin market share to drop from 58% in 2006 to 21% in 2016. The U.S. patent expiry of Zocor will prompt a rapid and extensive shift in prescribing to generic equivalents from 2007 onward as third-party payers remove the brand from formularies.

"Patient-share growth will be fastest for generic Zocor, which will overtake Lipitor for prescriptions in the majority of newly diagnosed PAD patients who may be unable to afford the high co-payments associated with Lipitor," said Mary Argent-Katwala, Ph.D., analyst at Decision Resources. "The decline in statin market share will then accelerate from 2011 to 2016 after the widespread patent expiry of Lipitor."

To listen to an interview with Dr. Argent-Katwala regarding the peripheral arterial disease drug market, please visit the Find Out More section of the Decision Resources home page on September 24, 2007, at http://www.DecisionResources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
2. High-Fidelity PCR with a Novel Polymerase Mixture
3. Challenge the Performance of Your Hot-Start PCRs with FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System
4. Combine High Yield, Great Accuracy and the Prevention of Carry-over Contamination by Using the Novel Expand High FidelityPLUS PCR System
5. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
6. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
9. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Life-sciences conference to feature novel research with clinical potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... it has become a Wonderware Certified System Integrator Partner. Huffman Engineering is ... Electric Software. , “The System Integrator Partner certification gives customers confidence that our ...
(Date:12/7/2016)... Dec. 7, 2016  Biocom, the association for the ... below following passage of 21 st Century Cures legislation ... 30 by a 392-26 vote and in the Senate on ... attributed to Joe Panetta , president & CEO of ... give hope to millions of patients around the world. The ...
(Date:12/7/2016)... ARBOR, Mich. , Dec. 7, 2016  Lycera ... modulatory medicines, announced today the initiation of a Phase ... LYC-30937- E nteric C oated, in patients with ... is estimated to affect as many as 7.5 million people ... approximately 1.5 - 3 million cases being diagnosed as ...
Breaking Biology Technology:
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/5/2016)... WASHINGTON , Dec. 5, 2016  The ... (NIJ), today published "Can CT Scans Enhance or ... examines the potential of supporting or replacing forensic ... a CT scan. In response to ... NIJ is exploring using CT scans as a ...
Breaking Biology News(10 mins):